Innate Pharma Collaborates with Sobi to License Lacutamab in Cutaneous T-cell Lymphoma (CTCL)

Shots: Innate Pharma & Sobi have entered into a strategic partnership to initiate P-III (TELLOMAK-3) trial of lacutamab in CTCL, supporting a planned accelerated approval filing in Sézary syndrome TELLOMAK-3 is expected to support full approval filings in Sézary syndrome & mycosis fungoides. Sobi will gain exclusive global commercialization rights upon potential accelerated approval &…

ByRidhi RastogiAugust 10, 2026

NEWS

The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome

Shots: The US FDA has granted BTD to lacutamab for the treatment of adults with r/r sézary syndrome after receiving ≥2L of therapy incl. mogamulizumab Designation was based on P-I as well as P-II (TELLOMAK) trial data, showing efficacy & favorable safety in pts who were heavily pre-treated with mogamulizumab Additionally, Lacutamab (anti-KIR3DL2…

ByRidhi RastogiFebruary 18, 2025

Innate Pharma Collaborates with Sobi to License Lacutamab in Cutaneous T-cell Lymphoma (CTCL)

The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome

Contact US

FOLLOW US